Central dopamine deficiency in pure autonomic failure

David S. Goldstein, Courtney Holmes, Takuya Sato, Miya Bernson, Neptune Mizrahi, Richard Imrich, Gilberto Carmona, Yehonatan Sharabi, Alexander Vortmeyer

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: Pure autonomic failure (PAF) and Parkinson's disease (PD) share several clinical laboratory abnormalities; however, PAF is not associated with parkinsonism. In this study, we tested the hypothesis that preservation of nigrostriatal dopaminergic innervation explains the absence of motor dysfunction in PAF. Methods: Patients with PAF (N = 5) or PD (N = 21) and control subjects (N = 14) had brain 6-[18F]fluorodopa positron emission tomographic scanning and cerebrospinal fluid catechol measurements. A patient with PAF and another with PD had rapid postmortem striatal, nigral, and sympathetic ganglion sampling, with assays of catechols and tyrosine hydroxylase activity. Results: The PAF and PD groups had similarly low mean substantia nigra (SN):occipital (OCC) ratios of 6-[18F]fluorodopa-derived radioactivity and similarly low cerebrospinal fluid dihydroxyphenylacetic acid and DOPA levels. Only the PD group, however, had low PUT:OCC, caudate:OCC, or PUT:SN ratios. The PAF and PD cases had similarly low SN tissue concentrations of dopamine and tyrosine hydroxylase activity, but the PD patient had tenfold lower PUT dopamine and the PAF patient 15-fold lower myocardial norepinephrine concentrations. Conclusions: Surprisingly, PAF and PD entail similarly severe nigral and overall central dopaminergic denervation. There is more severe loss of striatal dopaminergic terminals in PD than in PAF and more severe loss of sympathetic noradrenergic terminals in PAF than in PD. These differences explain the distinctive clinical manifestations of the two Lewy body diseases. Parkinsonism appears to reflect striatal dopamine deficiency rather than loss of nigral dopaminergic neurons per se.

Original languageEnglish (US)
Pages (from-to)58-65
Number of pages8
JournalClinical Autonomic Research
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Pure Autonomic Failure
Dopamine
Parkinson Disease
Substantia Nigra
Autonomic Nervous System Diseases
Corpus Striatum
Tyrosine 3-Monooxygenase
Parkinsonian Disorders
Cerebrospinal Fluid
Catechols
Lewy Body Disease
Sympathetic Ganglia
Dopaminergic Neurons
Denervation
Radioactivity

Keywords

  • DOPAC
  • Dopamine
  • Fluorodopa
  • Parkinson
  • Pure autonomic failure

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Clinical Neurology

Cite this

Goldstein, D. S., Holmes, C., Sato, T., Bernson, M., Mizrahi, N., Imrich, R., ... Vortmeyer, A. (2008). Central dopamine deficiency in pure autonomic failure. Clinical Autonomic Research, 18(2), 58-65. https://doi.org/10.1007/s10286-008-0457-0

Central dopamine deficiency in pure autonomic failure. / Goldstein, David S.; Holmes, Courtney; Sato, Takuya; Bernson, Miya; Mizrahi, Neptune; Imrich, Richard; Carmona, Gilberto; Sharabi, Yehonatan; Vortmeyer, Alexander.

In: Clinical Autonomic Research, Vol. 18, No. 2, 01.04.2008, p. 58-65.

Research output: Contribution to journalArticle

Goldstein, DS, Holmes, C, Sato, T, Bernson, M, Mizrahi, N, Imrich, R, Carmona, G, Sharabi, Y & Vortmeyer, A 2008, 'Central dopamine deficiency in pure autonomic failure', Clinical Autonomic Research, vol. 18, no. 2, pp. 58-65. https://doi.org/10.1007/s10286-008-0457-0
Goldstein DS, Holmes C, Sato T, Bernson M, Mizrahi N, Imrich R et al. Central dopamine deficiency in pure autonomic failure. Clinical Autonomic Research. 2008 Apr 1;18(2):58-65. https://doi.org/10.1007/s10286-008-0457-0
Goldstein, David S. ; Holmes, Courtney ; Sato, Takuya ; Bernson, Miya ; Mizrahi, Neptune ; Imrich, Richard ; Carmona, Gilberto ; Sharabi, Yehonatan ; Vortmeyer, Alexander. / Central dopamine deficiency in pure autonomic failure. In: Clinical Autonomic Research. 2008 ; Vol. 18, No. 2. pp. 58-65.
@article{d81ef44d38524a4c84ebde7b0d08178b,
title = "Central dopamine deficiency in pure autonomic failure",
abstract = "Objective: Pure autonomic failure (PAF) and Parkinson's disease (PD) share several clinical laboratory abnormalities; however, PAF is not associated with parkinsonism. In this study, we tested the hypothesis that preservation of nigrostriatal dopaminergic innervation explains the absence of motor dysfunction in PAF. Methods: Patients with PAF (N = 5) or PD (N = 21) and control subjects (N = 14) had brain 6-[18F]fluorodopa positron emission tomographic scanning and cerebrospinal fluid catechol measurements. A patient with PAF and another with PD had rapid postmortem striatal, nigral, and sympathetic ganglion sampling, with assays of catechols and tyrosine hydroxylase activity. Results: The PAF and PD groups had similarly low mean substantia nigra (SN):occipital (OCC) ratios of 6-[18F]fluorodopa-derived radioactivity and similarly low cerebrospinal fluid dihydroxyphenylacetic acid and DOPA levels. Only the PD group, however, had low PUT:OCC, caudate:OCC, or PUT:SN ratios. The PAF and PD cases had similarly low SN tissue concentrations of dopamine and tyrosine hydroxylase activity, but the PD patient had tenfold lower PUT dopamine and the PAF patient 15-fold lower myocardial norepinephrine concentrations. Conclusions: Surprisingly, PAF and PD entail similarly severe nigral and overall central dopaminergic denervation. There is more severe loss of striatal dopaminergic terminals in PD than in PAF and more severe loss of sympathetic noradrenergic terminals in PAF than in PD. These differences explain the distinctive clinical manifestations of the two Lewy body diseases. Parkinsonism appears to reflect striatal dopamine deficiency rather than loss of nigral dopaminergic neurons per se.",
keywords = "DOPAC, Dopamine, Fluorodopa, Parkinson, Pure autonomic failure",
author = "Goldstein, {David S.} and Courtney Holmes and Takuya Sato and Miya Bernson and Neptune Mizrahi and Richard Imrich and Gilberto Carmona and Yehonatan Sharabi and Alexander Vortmeyer",
year = "2008",
month = "4",
day = "1",
doi = "10.1007/s10286-008-0457-0",
language = "English (US)",
volume = "18",
pages = "58--65",
journal = "Clinical Autonomic Research",
issn = "0959-9851",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

TY - JOUR

T1 - Central dopamine deficiency in pure autonomic failure

AU - Goldstein, David S.

AU - Holmes, Courtney

AU - Sato, Takuya

AU - Bernson, Miya

AU - Mizrahi, Neptune

AU - Imrich, Richard

AU - Carmona, Gilberto

AU - Sharabi, Yehonatan

AU - Vortmeyer, Alexander

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Objective: Pure autonomic failure (PAF) and Parkinson's disease (PD) share several clinical laboratory abnormalities; however, PAF is not associated with parkinsonism. In this study, we tested the hypothesis that preservation of nigrostriatal dopaminergic innervation explains the absence of motor dysfunction in PAF. Methods: Patients with PAF (N = 5) or PD (N = 21) and control subjects (N = 14) had brain 6-[18F]fluorodopa positron emission tomographic scanning and cerebrospinal fluid catechol measurements. A patient with PAF and another with PD had rapid postmortem striatal, nigral, and sympathetic ganglion sampling, with assays of catechols and tyrosine hydroxylase activity. Results: The PAF and PD groups had similarly low mean substantia nigra (SN):occipital (OCC) ratios of 6-[18F]fluorodopa-derived radioactivity and similarly low cerebrospinal fluid dihydroxyphenylacetic acid and DOPA levels. Only the PD group, however, had low PUT:OCC, caudate:OCC, or PUT:SN ratios. The PAF and PD cases had similarly low SN tissue concentrations of dopamine and tyrosine hydroxylase activity, but the PD patient had tenfold lower PUT dopamine and the PAF patient 15-fold lower myocardial norepinephrine concentrations. Conclusions: Surprisingly, PAF and PD entail similarly severe nigral and overall central dopaminergic denervation. There is more severe loss of striatal dopaminergic terminals in PD than in PAF and more severe loss of sympathetic noradrenergic terminals in PAF than in PD. These differences explain the distinctive clinical manifestations of the two Lewy body diseases. Parkinsonism appears to reflect striatal dopamine deficiency rather than loss of nigral dopaminergic neurons per se.

AB - Objective: Pure autonomic failure (PAF) and Parkinson's disease (PD) share several clinical laboratory abnormalities; however, PAF is not associated with parkinsonism. In this study, we tested the hypothesis that preservation of nigrostriatal dopaminergic innervation explains the absence of motor dysfunction in PAF. Methods: Patients with PAF (N = 5) or PD (N = 21) and control subjects (N = 14) had brain 6-[18F]fluorodopa positron emission tomographic scanning and cerebrospinal fluid catechol measurements. A patient with PAF and another with PD had rapid postmortem striatal, nigral, and sympathetic ganglion sampling, with assays of catechols and tyrosine hydroxylase activity. Results: The PAF and PD groups had similarly low mean substantia nigra (SN):occipital (OCC) ratios of 6-[18F]fluorodopa-derived radioactivity and similarly low cerebrospinal fluid dihydroxyphenylacetic acid and DOPA levels. Only the PD group, however, had low PUT:OCC, caudate:OCC, or PUT:SN ratios. The PAF and PD cases had similarly low SN tissue concentrations of dopamine and tyrosine hydroxylase activity, but the PD patient had tenfold lower PUT dopamine and the PAF patient 15-fold lower myocardial norepinephrine concentrations. Conclusions: Surprisingly, PAF and PD entail similarly severe nigral and overall central dopaminergic denervation. There is more severe loss of striatal dopaminergic terminals in PD than in PAF and more severe loss of sympathetic noradrenergic terminals in PAF than in PD. These differences explain the distinctive clinical manifestations of the two Lewy body diseases. Parkinsonism appears to reflect striatal dopamine deficiency rather than loss of nigral dopaminergic neurons per se.

KW - DOPAC

KW - Dopamine

KW - Fluorodopa

KW - Parkinson

KW - Pure autonomic failure

UR - http://www.scopus.com/inward/record.url?scp=43049122373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049122373&partnerID=8YFLogxK

U2 - 10.1007/s10286-008-0457-0

DO - 10.1007/s10286-008-0457-0

M3 - Article

C2 - 18363034

AN - SCOPUS:43049122373

VL - 18

SP - 58

EP - 65

JO - Clinical Autonomic Research

JF - Clinical Autonomic Research

SN - 0959-9851

IS - 2

ER -